Reliability and validity of a point-of-care sural nerve conduction device for identification of diabetic neuropathy
Semaglutide weight loss mechanism #1: it prevents blood sugar spikes Well-functioning L-cells located in the gut produce natural GLP-1 after food intake, which inhibits potentially damaging postprandial glucose excursions (PPGEs) in laymens terms, post-meal blood sugar spikes (PPG inhibition is why, before the FDA approved GLP-1 analog semaglutide for weight loss therapy, it was commonly used in the treatment of diabetes.) This blood sugar-limiting effect mediated by a complex interplay of hormones is called glucose homeostasis. Semaglutide, a GLP-1 analog, does the same thing to regulate glucose homeostasis, but with greater efficacy due to the concentrated dosage used in therapy

If you fall into any of these buckets, microdosing is unlikely to solve the underlying problem: BMI over 35 with obesity-related conditions (Type 2 diabetes, hypertension, sleep apnea, PCOS) History of bariatric surgery with significant weight regain Plateaued at a microdose for more than 4 to 6 months with no meaningful progress Have tried microdosing twice or more and stopped both times Need to lose more than 50 pounds to reach a healthy weight At BodEvolve Bariatric & Cosmetic Surgery Center, dr Frenzel works with patients across Texas who came in thinking a GLP-1 microdose would be the answer, and left with a clearer plan that actually matched their goals
For any reconstituted peptide that will be stored and used over time, we strongly recommend using bacteriostatic water.
Enough dosing errors have been reported with compounded GLP-1 injectables (mis-calculated concentrations, wrong syringes, unit mix-ups) that in 2024, the FDA published a warning